170 related articles for article (PubMed ID: 32839486)
1. Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
Karimi S; Mansouri S; Mamatjan Y; Liu J; Nassiri F; Suppiah S; Singh O; Aldape K; Zadeh G
Sci Rep; 2020 Aug; 10(1):14115. PubMed ID: 32839486
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunosuppression in patients with high-grade meningiomas.
Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Koh YW; Lee SJ; Han JH; Haam S; Jung J; Lee HW
Lung Cancer; 2019 Mar; 129():41-47. PubMed ID: 30797490
[TBL] [Abstract][Full Text] [Related]
5. Distinct Expression Patterns of Carbonic Anhydrase IX in Clear Cell, Microcystic, and Angiomatous Meningiomas.
Chkheidze R; Cimino PJ; Hatanpaa KJ; White CL; Ferreira M; Piccirillo SGM; Li L; Rajaram S; Nyagilo JO; Burns DK; Raisanen JM; Cai C
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1081-1088. PubMed ID: 31589317
[TBL] [Abstract][Full Text] [Related]
6. Expression of carbonic anhydrase IX is associated with poor prognosis through regulation of the epithelial‑mesenchymal transition in hepatocellular carcinoma.
Hyuga S; Wada H; Eguchi H; Otsuru T; Iwgami Y; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Int J Oncol; 2017 Oct; 51(4):1179-1190. PubMed ID: 28849188
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in meningiomas.
Johnson MD
J Clin Neurosci; 2018 Nov; 57():149-151. PubMed ID: 30153998
[TBL] [Abstract][Full Text] [Related]
9. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
[TBL] [Abstract][Full Text] [Related]
10. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
Yoo H; Baia GS; Smith JS; McDermott MW; Bollen AW; Vandenberg SR; Lamborn KR; Lal A
Clin Cancer Res; 2007 Jan; 13(1):68-75. PubMed ID: 17200340
[TBL] [Abstract][Full Text] [Related]
11. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
[TBL] [Abstract][Full Text] [Related]
12. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Karimi S; Mansouri S; Nassiri F; Bunda S; Singh O; Brastianos PK; Dunn IF; Zadeh G
J Neurooncol; 2021 Feb; 151(3):443-449. PubMed ID: 33611710
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
